Mavacamten is a selective cardiac myosin inhibitor – a drug that reduces the heart muscle’s ability to contract.
It is used to treat obstructive hypertrophic cardiomyopathy (OHCM). This disease is characterised by a thickening of the heart muscle, usually the wall between the ventricles, which restricts the flow of blood from the heart to the rest of the body.
Mavacamten and the benefit of DNA analysis
The rate at which mavacamten is processed within your body varies from one individual to another. This means that the efficacy and side effects of mavacamten can be predicted to some extent on the basis of your genes. Preventive DNA analysis can therefore be an important tool in optimising your medication.
Also known as